MSF, in partnership with WHO and FIND, has led the development of a target product profile (TPP) for a multiplex multi-analyte diagnostic platform technology. Essentially, a test capable of detecting a wide array of different disease markers using a single patient sample. The three organizations now seek public comments on the draft.
Input from interested experts and stakeholders can be submitted before the deadline of 22 December 2017. The current draft is based on two rounds of stakeholder surveys and an in-person consensus meeting of diagnostic experts. Public comments are being collected through this google survey link. Survey responses will be collated and revisions considered to arrive at a final TPP.
A platform that meets the requirements described in the TPP would have a wide variety of applications, thus the current draft TPP is designed to be disease area agnostic, so that it could be adapted to specific needs ranging from communicable to non-communicable diseases. A parallel process is underway to prioritize a list of pathogens that should be targeted for the development of an assay for use on the platform, with severe febrile illness without a known source as the focus.